Thalidomide, the notorious drug which caused horrendous birth defects in the 1950s and 1960s, is close to making a comeback as an anticancer drug. Drug firm Celgene of Warren, New Jersey, has applied to European drug authorities for permission to sell thalidomide to treat multiple myeloma, a fatal cancer of the bone marrow. In clinical trials the drug performed well against the disease. It will take Europe seven months or more to reach a verdict on the drug, which will not be prescribed to pregnant women or those considering having children.
To continue reading, today with our introductory offers
Advertisement
More from New Scientist
Explore the latest news, articles and features
Popular articles
Trending New Scientist articles
1
Remote-controlled cockroach swarm can now breathe underwater
2
Where, when and how to watch the 2026 solar eclipse
3
We鈥檝e uncovered a master gene that switches on human development
4
The best sci-fi novel in 2026 so far 鈥 plus 6 other great reads
5
Our verdict on The Selfish Gene: An unpopular piece of popular science
6
If you aren't terrified by this heatwave, you should be
7
You should turn off fans when it's too hot 鈥 but how hot is too hot?
8
Fully autonomous drones have killed human soldiers for the first time
9
I have a 100 per cent chance of getting cancer due to a rare gene
10
Ancient human DNA found on cave art for the first time
